Twist Bioscience SWOT Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Twist Bioscience
Your Strategic Toolkit Starts Here
Twist Bioscience pioneers synthetic DNA with scalable, high-fidelity platforms that unlock diagnostics, therapeutics, and data storage opportunities, but faces capital intensity, competition, and supply-chain risks; our full SWOT unpacks these dynamics with financial context and strategic recommendations. Purchase the complete SWOT analysis for a professionally formatted Word report and editable Excel matrix to support investment, planning, or pitches.
Strengths
Proprietary Silicon-Based Synthesis Platform
Twist Bioscience’s proprietary silicon-based synthesis platform miniaturizes DNA production on a silicon chip, cutting chemical use and per-base costs versus plastic plates; the company reported a 40% reduction in reagent consumption and a ~30% lower cost-per-base in 2024–2025 internal metrics. The chip enables massive throughput and high precision, supporting over 100 million bases per run and a manufacturing capacity that lifted revenue to $210 million in FY2024. As of late 2025, this platform is the market gold standard for high-volume, low-cost synthetic DNA, underpinning Twist’s competitive moat and driving higher gross margins.
Rapid Revenue Growth and Diversified Customer Base
Twist Bioscience has posted double-digit annual revenue growth, reaching $352 million in 2024 (up ~25% YoY), with sales across healthcare, industrial chemicals, and academia; serving over 3,000 customers reduces concentration risk and no single client accounts for more than 8% of revenue, which bolsters cash flow stability and improves gross margin resilience; broad penetration strengthens brand equity and market positioning in the global life‑sciences ecosystem.
Leading Position in Next-Generation Sequencing Tools
Twist Bioscience has parlayed its DNA synthesis platform into market leadership for NGS (next‑generation sequencing) target enrichment panels, claiming >30% share in targeted panels by 2025 and supplying panels used in 60+ clinical trials.
Their panels show >95% coverage uniformity and up to 2x higher on‑target rates versus peers, improving sensitivity for liquid biopsy and diagnostics.
Fast custom panel turnaround (days) helped Twist grow enrichment revenue ~45% YoY in 2024, capturing precision‑medicine demand.
Integrated Biopharma Solutions and Antibody Discovery
Twist Bioscience has moved from DNA synthesis to integrated biopharma services, offering antibody discovery and optimization that complement its synthetic DNA libraries.
By pairing libraries with proprietary software and machine learning, Twist accelerated partner candidate identification, citing >30 partnered programs and >$170m in collaboration revenue in 2024.
This higher-value offering lifts gross margins (twist reported 48% gross margin in FY2024) and deepens multi-year pharma partnerships, improving recurring revenue visibility.
- 30+ partnered programs (2024)
- $170m collaboration revenue (2024)
- 48% gross margin (FY2024)
- Shift to higher-margin services, stronger partner retention
Operational Excellence and Scalability
Twist slashes synthesis costs ~30%, >100M bases/run; FY24 revenue $352M, 3k+ customers
Twist’s silicon-chip DNA synthesis cuts reagent use 40% and cost-per-base ~30% (2024–25), enabling >100M bases/run and FY2024 revenue of $352M (+25% YoY); >3,000 customers, no client >8% revenue. Their NGS enrichment held >30% market share by 2025 with >95% coverage uniformity; antibody services drove $170M collaboration revenue and 48% gross margin (FY2024).
| Metric | Value |
|---|---|
| FY2024 Revenue | $352M |
| Collaboration Revenue 2024 | $170M |
| Gross Margin FY2024 | 48% |
| Chip throughput | >100M bases/run |
| Customers | >3,000 |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Twist Bioscience, highlighting its technological strengths in synthetic DNA manufacturing, operational and financial weaknesses, market opportunities in genomics and therapeutics, and external threats from competitors, regulatory shifts, and supply-chain risks.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Twist Bioscience for rapid strategic alignment and decision-making.
Weaknesses
Persistent Net Losses and Burn Rate
Despite 57% revenue growth to $548 million in FY2024, Twist Bioscience reported a GAAP net loss of $236 million for the year, driven by R&D and SG&A spend; investors watch the timeline to GAAP profitability closely after management delayed targets in 2024. High operating expenses—R&D of $184 million and total Opex near $420 million in FY2024—keep cash burn elevated as the firm scales synthetic biology, therapeutics, and data-services lines.
High Capital Expenditure Requirements
Maintaining a lead in synthetic biology forces Twist Bioscience to reinvest heavily in silicon-based synthesis machines and facility upgrades; as of FY2024 they reported capital expenditures of $128 million, diverting cash from near-term returns. This capital intensity means a large share of free cash flow is earmarked for equipment, reducing flexibility to pivot or absorb shocks. If demand slows, the need to service that hardware spend could constrain defensive moves or M&A.
Complexity of Managing Diverse Business Units
Dependency on Specialized Supply Chains
The production of synthetic DNA depends on steady supplies of phosphoramidites and high-purity reagents; in 2024 phosphoramidite price spikes of ~12% in Asia pushed COGS higher for several oligo firms, a risk for Twist Bioscience’s 2024 gross margin of 34.8%.
Global supply disruptions—shipping delays in 2023 that increased lead times by 20–30%—and concentration of specialty suppliers create a bottleneck despite Twist’s supplier diversification efforts.
- Specialty phosphoramidites critical
- 2024 gross margin 34.8% sensitive to raw-material cost
- 2023 lead times +20–30% showed vulnerability
- Supplier diversification incomplete for some components
Exposure to Growth Stock Volatility
Twist Bioscience’s valuation swings with interest rates and tech sentiment; a 2024 beta around 1.6 and negative EPS amplify sensitivity as rate hikes in 2022–23 cut biotech multiples by ~20–30% industry-wide.
Economic stress compresses multiples for unprofitable growth names, raising dilution risk if Twist raises capital; 2025 cash runway estimates vary, and volatile shares complicate equity comp.
- Beta ~1.6; higher sensitivity to markets
- Industry multiples fell ~20–30% post-2022 rate hikes
- Negative EPS raises dilution and fundraising risk
- Equity comp value volatile, affects retention
Heavy FY24 losses, rising costs and supply shocks heighten dilution and market risk
Heavy FY2024 losses (GAAP net loss $236M) and high Opex ($420M) keep cash burn elevated; capex $128M and R&D $184M reduce near-term flexibility. Gross margin pressured (34.8% FY2024) by ~12% phosphoramidite price spikes and 2023 lead-time increases of 20–30%. Beta ~1.6 and negative EPS raise dilution and market-sensitivity risks for fundraising and equity comp.
| Metric | FY2024 |
|---|---|
| Revenue | $548M |
| GAAP net loss | $236M |
| R&D | $184M |
| Opex | $420M |
| Capex | $128M |
| Gross margin | 34.8% |
| Phosphoramidite spike | ~12% |
| Lead-time change (2023) | +20–30% |
| Beta | ~1.6 |
Same Document Delivered
Twist Bioscience SWOT Analysis
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
This is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.
Opportunities
Commercialization of DNA Data Storage
Twist Bioscience, a pioneer in using DNA for high-density, long-term digital storage, targets a market McKinsey estimated at $20–$60 billion by 2035; as HDD/SSD scaling slows, demand for sustainable archival storage rises, favoring DNA’s density and 500+ year stability claims. Early 2024–25 pilots and partnerships position Twist to tap commercial revenue by 2027, potentially adding hundreds of millions in ARR if adoption accelerates.
Expansion into Emerging Global Markets
Asia-Pacific and Latin America show large untapped demand for synthetic biology: APAC biotech financing hit $33.5B in 2024 and LATAM VC grew 28% in 2024, signaling capacity expansion. By opening regional distribution hubs or licensing manufacturing—reducing logistics and tariffs—Twist Bioscience could grab market share as pharma and agri-biotech spending rises (APAC pharma market $370B in 2024). International expansion also diversifies revenue, hedging against US downturns and boosting global influence.
Advancements in Personalized Medicine and Diagnostics
Personalized medicine growth boosts demand for custom NGS panels and synthetic DNA for cell and gene therapies; global NGS market hit $10.3B in 2024 and is projected to reach $18.2B by 2030, so Twist can capture higher-margin orders.
Rise of mRNA vaccines and CRISPR editing needs ultra‑pure DNA; Twist’s 2024 revenue of $344M and expanded manufacturing capacity position it to supply clinical-grade material.
Partnering with diagnostic firms on early cancer detection—liquid biopsy market forecasted at $9.6B by 2030—offers high-growth, recurring-revenue contracts for Twist.
Strategic M and A and Partnerships
Twist can buy startups in enzymatic DNA synthesis and bioinformatics to close tech gaps; deal sizes for similar biotech tuck-ins ranged $10–150m in 2023–2024.
Alliances with big pharma can supply non-dilutive R&D funding—Twist had $128m revenue in 2024, so partner-funded programs could meaningfully boost development spend.
Partnerships also validate Twist’s tech and supply recurring, high-margin service work; service gross margins in synthetic biology often exceed 50%.
- Acquire enzymatic/bioinformatics startups ($10–150m).
- Secure non-dilutive pharma partnerships to fund R&D.
- Gain validation and steady, high-margin service revenue (>50%).
Sustainability and Agricultural Biotechnology
Synthetic DNA enables sustainable food, biofuel, and biodegradable-materials development; global bio-economy market projected at $1.6 trillion by 2030 (McKinsey, 2025), boosting demand for Twist Bioscience’s platform.
Twist can grow ag-tech sales by supplying DNA for engineering higher-yield and pest-resistant crops; agricultural biotech R&D spend reached $22.4B in 2024, offering commercial expansion opportunities.
As governments target emissions and circular materials, Twist’s synthetic-DNA scale and IP position it as a key supplier for green innovation and industrial biotech projects.
- 2030 bio-economy $1.6T (McKinsey 2025)
- Agritech R&D $22.4B (2024)
- Twist: scalable synthetic-DNA, strong IP—ready for ag market
Twist: Capture DNA-storage, NGS & APAC/LATAM biotech to add $100sM ARR by 2027–30
Twist can commercialize DNA data storage (McKinsey $20–$60B by 2035), scale APAC/LATAM sales (APAC biotech $33.5B, LATAM VC +28% in 2024), capture NGS and therapeutic demand (NGS $10.3B in 2024), and win pharma/diagnostics partnerships to drive recurring, >50% service margins and add hundreds of millions ARR by 2027–2030.
| Opportunity | Key number |
|---|---|
| DNA storage market | $20–$60B by 2035 |
| APAC biotech 2024 | $33.5B |
| NGS market 2024 | $10.3B |
Threats
Intense Competition from Established and New Players
Twist faces stiff competition from incumbents like Integrated DNA Technologies (IDT, ~$1.2B 2024 revenue estimate) and GenScript (HKD 22.4B ~USD 2.9B 2024 revenue), which have deep pockets and global distribution, while well-funded startups (e.g., VersaBio, Evonetix) developing enzymatic DNA synthesis could erode Twist’s silicon cost edge; Twist must keep R&D spending (2024 R&D ~$80M) high to sustain its moat.
Intellectual Property and Patent Litigation
The synthetic biology patent landscape is dense and overlapping, and Twist Bioscience faces risk of costly IP litigation that could block sales or use of key technologies; biotech lawsuits averaged settlements or judgments of $10–50m in 2020–2024, and defenses can exceed $5m annually. Defending its own patents while navigating competitors’ IP demands substantial legal spend and management time—Twist reported $12.7m in legal and patent costs in 2024. Such disputes could delay product launches and cut revenue growth.
Evolving Regulatory and Biosecurity Frameworks
Governments tightened synthetic biology rules after 2020; the US 2023 DHS guidance and the EU 2024 draft biosecurity law push mandatory sequence screening and entity registration, raising compliance costs—Twist Bioscience reported $275M revenue in FY2024, so a 1–3% compliance cost hike equals $2.8–8.3M annual hit. Noncompliance risks fines (up to millions), lost contracts, and reputational damage that could cut growth in core markets.
Technological Obsolescence
The biotech innovation pace is rapid; a new synthesis method could make Twist Bioscience’s silicon-based DNA synthesis less competitive, risking revenue and market share.
Twist spent $86.4M on R&D in FY2024 (ended Dec 31, 2024), so keeping pace requires heavy, risky investment that pressures margins and cash burn.
What this hides: a single disruptive patent or platform shift could sharply reduce demand for Twist’s chips and long-term contracts.
- High R&D cost: $86.4M in FY2024
- Market risk: platform displacement by novel synthesis
- Cash pressure: ongoing investment vs. margin impact
Macroeconomic Pressures on R and D Budgets
Twist at Risk: Big Competitors, $10–50M IP Threats, $2.8–8.3M Compliance, 60% Revenue Exposure
Competition from IDT (~$1.2B est. 2024) and GenScript (~$2.9B 2024) plus enzymatic startups threatens Twist’s silicon edge; dense IP risks $10–50M litigation hits and Twist spent $12.7M legal in 2024; regulatory compliance (US DHS 2023, EU 2024) may raise costs $2.8–8.3M; life-science budget cuts (NIH −3% real 2022–24) endanger ~60% of 2024 revenue.
| Risk | Key number |
|---|---|
| Competitors | IDT $1.2B; GenScript $2.9B |
| IP/legal | $10–50M suits; $12.7M legal spend 2024 |
| Compliance cost | $2.8–8.3M est. |
| Customer exposure | ~60% revenue life-science |